Monitor for future product schedules that will reveal pricing and volume details, as well as regulatory updates on sonelokimab that could affect commercial launch timing and demand for manufacturing capacity.
Price Chart
Executive Summary
MoonLake Immunotherapeutics entered into a Master Commercial Supply Agreement and Capacity Agreement with Vetter Pharma for commercial manufacturing of pre-filled devices for its lead candidate sonelokimab. The agreement includes binding minimum and maximum capacity commitments but no financial terms were disclosed. This is a routine operational step forward for the company as it prepares for potential commercial launch.
Key Facts
- Entered into Master Commercial Supply Agreement with Vetter Pharma International GmbH for manufacturing of pre-filled application systems for sonelokimab.
- Simultaneously signed a Capacity Agreement with binding minimum quantity commitments and a maximum quantity cap.
- Product-specific pricing and terms will be detailed in future schedules under the master agreement.
- Termination provisions include change-of-control clauses and 12-month notice for no-cause termination.
Financial Impact
No financial terms disclosed; capacity commitments may carry compensation obligations if minimum orders not met.
Risk Factors
- Capacity commitment could become a financial burden if sonelokimab fails to gain regulatory approval or commercial traction.
- No financial terms disclosed, making it difficult to assess potential impact on operating expenses.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-063125 |
| Document: 0001213900-26-063125-index-headers.html | 0001213900-26-063125 |
| Document: 0001213900-26-063125-index.html | 0001213900-26-063125 |
| Document: 0001213900-26-063125.txt | 0001213900-26-063125 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | Institutional Cluster | $17.23 | awaiting T+60 | — | $11.85 (−31.22%) |
Aug 10, 2026 11w ago | 8-K | $17.33 | awaiting T+60 | — | $11.85 (−31.62%) |
Aug 10, 2026 11w ago | Press Release | $17.33 | awaiting T+60 | — | $11.85 (−31.62%) |
Jul 20, 2026 14w ago | Insider Cluster | $19.05 $10.41 | ▲ +45.35% | ▲ +50.19% | $11.85 (+37.80%) |
Jun 25, 2026 17w ago | 8-K | $19.99 $12.39 | ▲ +38.02% | ▲ +41.87% | $11.85 (+40.72%) |
Jun 23, 2026 17w ago | Press Release | $20.00 $12.20 | ▲ +39.00% | ▲ +42.29% | $11.85 (+40.75%) |
Jun 22, 2026 18w ago | 8-K | $22.16 $12.20 | ▼ −44.95% | ▼ −46.69% | $11.85 (−46.53%) |
Jun 21, 2026 18w ago | Press Release | $22.16 $12.20 | ▼ −44.95% | ▼ −46.69% | $11.85 (−46.53%) |
Jun 11, 2026 19w ago | Institutional Cluster | $17.75 $15.01 | ▲ +15.44% | ▲ +19.83% | $11.85 (+33.24%) |
Jun 1, 2026 21w ago | 8-K | $18.82 $15.56 | ▼ −17.32% | ▼ −18.55% | $11.85 (−37.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers